Christine A. Mundkur
Christine A. Mundkur, Former CEO of Impopharma, Inc.
- CEO and non-voting Chair of the Board of Directors at Impopharma Inc., a generic pharmaceutical inhalation development company, from 2013 until 2017
- President of CM Strategic Advisors, consulting on global pharmaceutical business strategies, from 2011 until 2013
- President and CEO of the U.S. Division and Head of Commercial Operations for North America for Sandoz, Inc., a division of the Novartis Group and a global generic and biosimilar pharmaceutical business, from 2009 until 2010
- CEO of Barr Laboratories Inc., a subsidiary of Barr Pharmaceuticals Inc., in 2008 until Barr Pharmaceuticals was acquired by Teva Pharmaceutical Industries Ltd.
- Associate Counsel at Barr Pharmaceuticals and held several positions of increasing responsibility in the company’s quality and regulatory departments, from 1993 until 2008
- Other current public company directorships: MannKind Corporation, a global biopharmaceutical company focused on treatments for diabetes, since 2018
- Prior public company directorships within the last five years: Lupin Limited, an Indian multinational pharmaceutical company, from 2019 until 2022
Director Since 2022